India’s BDR Files Compulsory License For BMS’ Sprycel; Next Up Ixempra And Herceptin?
This article was originally published in PharmAsia News
Executive Summary
Little-known Indian drug manufacturer BDR International has prepared a blueprint to launch copies of patent-protected cancer drugs, opening a new front in a battle over IP rights that has already engulfed Bayer’s Nexavar.